march 19 tirzepatide Shortage Ends Eli Lilly launches weight-loss drug

however, this analysis is limited by a large proportion of data missingness (Supplementary Table S1).The pattern of association of GLP1-RA with decreased acute healthcare utilization, CKD progression and all-cause death despite no difference in CV outcomes persisted in additional analyses excluding patients with ESRD (Supplementary Table S2) and after adjusting for A1c at follow-up and use of other anti-hyperglycemic medications (Supplementary Table S3)

Li T, Tan Y, Ouyang S, He J, Liu L

It was also recently approved for sleep apnea in people with obesity

Circana looked at foodservice trends related to GLP-1s and found that casual dining has experienced the largest increase among weight-loss users, the research firm said

seek urgent medical advice for symptoms of severe hyperglycaemia including confusion, extreme thirst, or drowsiness

In line with Danish clinical guidelines, patients were modelled as remaining on the trial medications until the HbA1c level target of 7.5% was exceeded by 0.5% [38] (i.e., when the HbA1c level crossed 8.0%), at which point a switch to a basal insulin (+ metformin) regimen was estimated and treatment effects of trial medications were reversed across biomarkers